Hero Banner

News Releases

Ultralife Corporation
Oct 27, 2022
Ultralife Corporation Reports Third Quarter Results

Dial in number(s)

USA Local: +1 (0) 786 697 3501
USA Toll Free: 866 580 3963

NEWARK, N.Y., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported an operating loss of $0.6 million and adjusted EBITDA of $1.3 million on revenue of $33.2 million for the third quarter ended September 30, 2022. For the third quarter of 2021, the Company reported an operating loss of $0.8 million and adjusted EBITDA of $0.3 million on revenue of $21.8 million.

“For the third quarter, government/defense revenue doubled year-over-year reflecting higher demand from our customers in Battery & Energy Products and shipments of larger awards in Communications Systems. This increase in government/defense revenue along with the addition of Excell, resulted in a 53% increase in total Company revenue. While we benefited from the operating expense leverage of the sharp revenue gain, the combination of production inefficiencies associated with supply chain disruptions and input cost inflation severely pressured gross margins and profitability for the quarter,” said Michael D. Popielec, President and Chief Executive Officer. “We continue to work on offsetting inflation and manufacturing workflow challenges with price realization and productivity gains to restore profitable growth. With a backlog now over $100 million, we are positioned well for near-term revenue increases and remain committed to advancing several transformational projects and new product opportunities to drive long-term revenue growth.”

Third Quarter 2022 Financial Results

Revenue was $33.2 million, an increase of $11.5 million, or 52.7%, compared to $21.8 million for the third quarter of 2021. Overall, government/defense sales increased 99.8% and commercial sales increased 38.0% from the 2021 period. Battery & Energy Products revenue increased 42.9% to $28.6 million, compared to $20.0 million last year, reflecting $6.9 million of Excell sales coupled with organic increases of 66.4% in government/defense sales, 7.4% in oil & gas market sales and 2.4% in industrial market sales, partially offset by a 12.1% decrease in medical sales. Net organic sales for this segment increased 8.5%. Communications Systems sales increased 165.3% to $4.7 million compared to $1.8 million for the same period last year, despite lingering supply chain disruptions resulting in delays in our shipments to future periods.   Our total backlog exiting the third quarter grew to $106.2 million, which represents an increase of $27.0 million or 34.1% over the comparable backlog exiting the prior quarter and an increase of $64.2 million or 153.3% over that exiting the third quarter of 2021.

Gross profit was $6.7 million, or 20.2% of revenue, compared to $5.1 million, or 23.5% of revenue, for the same quarter a year ago.   Battery & Energy Products’ gross margin was 18.7% compared to 24.0% last year, primarily due to supply chain disruptions including component cost inflation, prolonged lead times and logistics delays, and the incremental costs of transitioning new products to high volume production. Communications Systems gross margin was 29.5% compared to 18.0% last year, primarily due to higher factory volume and more favorable sales mix.  

Operating expenses were $7.3 million compared to $5.9 million last year, an increase of 24.0% , reflecting $1.1 million for Excell. Operating expense ratio to revenue was 22.0%, a 510 basis-point improvement as compared to 27.1% of revenue for the year-earlier period.

Operating loss was $0.6 million compared to $0.8 million last year.

Net loss was $0.2 million or $0.01 per diluted share on a GAAP basis compared to a net loss of $0.6 million or $0.04 per diluted share for the third quarter of 2021.  

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense, was $1.3 million or 3.8% of sales for the third quarter of 2022, compared to $0.3 million or 1.3% of sales for the year-earlier period.

See the “Non-GAAP Financial Measures” section of this release for a reconciliation of Adjusted EPS to EPS and adjusted EBITDA to net (loss) income attributable to Ultralife Corporation.

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

Conference Call Information

Ultralife will hold its third quarter earnings conference call today at 8:30 AM ET. To participate in the live call, please dial 786 697 3501 at least ten minutes before the scheduled start time, identify yourself and ask for the Ultralife call. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include the impact of COVID-19 and related supply chain disruptions, potential reductions in revenues from key customers, acceptance of our new products on a global basis and uncertain global economic conditions. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

Company Contact:  Investor Relations Contact:
Ultralife Corporation LHA
Philip A. Fain   Jody Burfening
(315) 210-6110  (212) 838-3777
pfain@ulbi.com  jburfening@lhai.com 


(Dollars in Thousands)

                                                                 September 30,
  December 31,
Current Assets:      
Cash $5,051   $8,413
Trade Accounts Receivable, Net 26,876   20,232
Inventories, Net 40,769   33,189
Prepaid Expenses and Other Current Assets 6,241   4,690
Total Current Assets 78,937   66,524
Property, Plant and Equipment, Net 21,898   23,205
Goodwill 37,066   38,068
Other Intangible Assets, Net 16,095   17,390
Deferred Income Taxes, Net 11,963   11,472
Other Non-Current Assets 1,981   2,879

           Total Assets
$167,940   $159,538

Current Liabilities:
Accounts Payable $15,827   $9,823
Current Portion of Long-Term Debt 2,000   2,000
Accrued Compensation and Related Benefits 2,000   1,842
Accrued Expenses and Other Current Liabilities 8,254   5,259
Total Current Liabilities 28,081   18,924
Long-Term Debt, Net 20,874   18,857
Deferred Income Taxes 1,996   2,254
Other Non-Current Liabilities 1,673   1,760
Total Liabilities 52,624   41,795
Shareholders' Equity:      
Common Stock 2,057   2,052
Capital in Excess of Par Value 187,181   186,518
Accumulated Deficit (47,727)   (47,832)
Accumulated Other Comprehensive Loss (4,842)   (1,653)
Treasury Stock (21,480)   (21,469)
Total Ultralife Equity 115,189   117,616
Non-Controlling Interest 127   127
Total Shareholders’ Equity 115,316   117,743
Total Liabilities and Shareholders' Equity $167,940   $159,538


(In Thousands Except Per Share Amounts)
  Three-Month Period Ended   Nine-Month Period Ended
  September 30,   September 30,   September 30,   September 30,
  2022   2021   2022    2021
Battery & Energy Products $28,583   $20,008   $87,873   $64,994
Communications Systems 4,651   1,753   7,860   9,510
Total Revenues 33,234   21,761   95,733   74,504
Cost of Products Sold:              
Battery & Energy Products 23,238   15,216   68,656   48,750
Communications Systems 3,281   1,437   5,758   6,401
Total Cost of Products Sold 26,519   16,653   74,414   55,151
Gross Profit 6,715   5,108   21,319   19,353
Operating Expenses:              
Research and Development 1,896   1,723   5,425   5,223
Selling, General and Administrative 5,405   4,164   15,982   12,866
Total Operating Expenses 7,301   5,887   21,407   18,089
Operating (Loss) Income (586)   (779)   (88)   1,264
Other (Income) Expense (254)   (1)   (22)   76
(Loss) Income Before Income Taxes (332)   (778)   (66)   1,188
Income Tax (Benefit) Provision (90)   (175)   (171)   290
Net (Loss) Income (242)   (603)   105   898
Net (Loss) Income Attributable to Non-Controlling Interest (3)   (18)   -   1
Net (Loss) Income Attributable to Ultralife Corporation ($239)   ($585)   $105   $897
Net (Loss) Income Per Share Attributable to Ultralife Common Shareholders – Basic ($.01)   ($.04)   $.01   $.06
Net (Loss) Income Per Share Attributable to Ultralife Common Shareholders – Diluted ($.01)   ($.04)   $.01   $.06
Weighted Average Shares Outstanding – Basic 16,133   16,065   16,122   16,020
Weighted Average Shares Outstanding – Diluted 16,133   16,065   16,144   16,200


Non-GAAP Financial Measures:

Adjusted EBITDA

In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to GAAP financial measures. We define adjusted EBITDA as net income (loss) attributable to Ultralife Corporation before net interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile adjusted EBITDA to net income (loss) attributable to Ultralife Corporation, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

(Dollars in Thousands)


  Three-Month Period Ended   Nine-Month Period Ended
  September 30, 2022   September 30, 2021   September 30, 2022   September 30, 2021
Net (Loss) Income Attributable to Ultralife Corporation ($239)   ($585)   $105   $897
Interest and Financing Expense 272   53   583   164
Income Tax (Benefit) Provision (90)   (175)   (171)   290
Depreciation Expense 815   700   2,450   2,160
Amortization Expense 318   148   969   458
Stock-Based Compensation Expense 179   142   552   512
Non-Cash Purchase Accounting Adjustment -   -   55   -
Adjusted EBITDA $1,255   $283   $4,543   $4,481